Revolutionizing Type 2 Diabetes Care in Primary Settings.

Primary care providers (PCPs) manage over 75% of patients with type 2 diabetes (T2D) in the United States. Recent updates to the American Diabetes Association's Standards of Care in Diabetes guideline require PCPs to reframe approaches to diabetes pharmacotherapy and educate patients on the importance of managing cardiorenal and metabolic risk in addition to glucose levels. SGLT2 inhibitors and GLP-1 receptor agonists are recommended first-line medications for T2D patients with heart failure and chronic kidney disease. The new paradigm of diabetes management emphasizes cardiorenal risk reduction and weight management in addition to focusing on glucose control and the prevention and management of microvascular and macrovascular complications with non–glucose lowering agents.